GNC launches ViraBLOC

PITTSBURGH GNC on Tuesday announced the launch of ViraBLOC, a clinically-tested immune defense product based on patent-pending elderberry extract from HerbalScience Group.

The latest clinical study on ViraBLOC complements other clinical studies on the immune system benefits of elderberry extract, GNC stated.

“ViraBLOC is the right product at the right time,” stated Beth Kaplan, GNC president and chief merchandising/marketing officer. “Elderberry extract has been recognized as a natural boost to the immune system for hundreds of years. What GNC has done is provide these benefits in an easy-to-take lozenge form that incorporates a clinically proven, patent-pending ingredient.”